المنتجات
| الفعالية | 1.25 mg/ml, 2.5 mg/ml |
|---|---|
| الحجم | 1 ml |
| نظام التصنيف الكيميائي العلاجي | C01CX08 |
Cardiac simulants
Therapeutic indications
Indicated for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate.
*Under development
| الفعالية | 10 mg/ml |
|---|---|
| الحجم | 2 ml, 4 ml, 5 ml |
| نظام التصنيف الكيميائي العلاجي | C03CA01 |
Diuretic
Therapeutic indications
Indicated when no adequate diuresis is achieved with oral administration of furosemide or when oral use is not possible:
- oedemas and/or ascites secondary to cardiac or hepatic disorders
- oedemas secondary to renal disorders
- oedemas secondary to burns
- pulmonary oedema (e.g. in acute heart failure)
- supportive measure in cerebral oedema
- oliguria secondary to gestosis, if necessary after correction of a hypovolaemic state (NB: oedemas and/or hypertension in cases of gestosis are not an indication)
- hypertensive crisis (in addition to other therapeutic measures)
| الفعالية | 5 mg/ml |
|---|---|
| الحجم | 5 ml, 10 ml |
| نظام التصنيف الكيميائي العلاجي | C02CA06 |
خافض إرتفاع ضعط الدم
* قيد التطوير
| الفعالية | 1 mg/ml |
|---|---|
| الحجم | 1 ml, 2 ml, 4 ml, 5 ml, 8 ml, 10 ml, 25 ml |
| نظام التصنيف الكيميائي العلاجي | C01CA03 |
منبه ومحفز قلبي